Los Angeles Capital Management LLC Has $642,000 Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

Los Angeles Capital Management LLC lessened its stake in Replimune Group, Inc. (NASDAQ:REPL) by 18.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 58,587 shares of the company’s stock after selling 13,228 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Replimune Group were worth $642,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in REPL. Millennium Management LLC raised its position in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after purchasing an additional 699,679 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Replimune Group in the 1st quarter valued at about $1,088,000. Acadian Asset Management LLC acquired a new stake in Replimune Group in the 1st quarter valued at about $927,000. Finally, Cubist Systematic Strategies LLC increased its position in Replimune Group by 282.2% during the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after buying an additional 53,313 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on REPL. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Tuesday, November 12th. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Replimune Group has a consensus rating of “Buy” and an average price target of $16.80.

Replimune Group Stock Performance

Shares of NASDAQ REPL opened at $10.80 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 13.46. The firm has a market cap of $738.94 million, a price-to-earnings ratio of -3.54 and a beta of 1.19. The stock’s fifty day moving average price is $11.46 and its two-hundred day moving average price is $9.57. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $12.97.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, equities analysts forecast that Replimune Group, Inc. will post -3.05 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.